Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).
暂无分享，去创建一个
T. Molina | B. Coiffier | J. Jais | H. Tilly | C. Haioun | M. André | A. Delmer | L. Ysebaert | M. Meignan | S. Bardet | J. Gabarre | F. Morschhauser | C. Fruchart | C. Thieblemont | A. Berriolo-Riedinger | R. Casasnovas | I. Plantier | G. Lepeu | D. Sénécal | S. Bologna